I Invested in Ozempic—It Taught Me a Valuable Lesson

I haven’t always been passionate about investing. My journey began out of necessity and curiosity. I noticed a lack of women in the investing space, and that piqued my interest.

I began investing in my teens. I taught myself through books, podcasts, and trial and error. It’s been a journey of empowerment and education, which I now aim to share with other women.

I first heard about Ozempic through financial news when its parent company, Novo Nordisk, started to gain traction in the stock market due to the drug’s popularity. Novo Nordisk is a global healthcare company with a strong focus on diabetes care, obesity treatments, and a range of other chronic diseases.

My initial thoughts were focused on the potential health impacts and ethical considerations. From an investment standpoint, I observed the market’s reaction and analyzed the company’s performance and the drug’s market potential before making any decisions.

I always approach investments with a balanced perspective, considering both the potential returns and the ethical implications. With Ozempic, I carefully evaluated the situation before deciding. Every investment carries risks, and it’s about managing those risks and making informed decisions.

Personally, my thoughts on the medication are complex. While I recognize its medical benefits for specific health conditions, I also consider the broader societal impacts and ethical considerations. Whether I would try it myself would depend on a range of factors, including medical advice and personal health needs.

Read more: 7 Long-Term Investment Strategies for 2024

In terms of exact figures, when it comes to investing, I always aim for long-term growth rather than quick gains, emphasizing the importance of patience and strategy in investing.

Simran Kaur ozempic
Simran Kaur (pictured L & R) began investing in her teens. She is now the founder of ‘Girls That Invest’, an initiative aimed at helping women from all walks of life to start investing.

Simran Kaur

Currently, ​Novo Nordisk’s sales increase is expected to approach $8 billion in 2024, with the company anticipated to land into the top 10 list of pharmaceutical companies by sales, potentially exceeding $40 billion—it is now more valuable than Tesla.

Before Ozempic, my investments were diverse, including stocks, bonds, and ETFs. I believe in a diversified portfolio to mitigate risks and maximize potential returns. Each investment has taught me valuable lessons about the market and myself.

For those looking to invest, my advice is to start small, educate yourself, and don’t be afraid to ask questions. Investing is not just for the wealthy, it’s for anyone willing to learn and grow their wealth over time. Understand your risk tolerance and financial goals, and invest in what you believe in.

Read more: Investment Portfolio: What It Is and How to Build a Good One

As for my future plans, I aim to continue educating and empowering women in investing. I’m focused on expanding the Girls That Invest Media community and providing resources that make investing accessible and understandable for all women. The journey is just beginning, and there’s so much more to learn and share!

With only 15 to 25 percent of women investing, globally recognized investor, Simran Kaur, founded Girls That Invest, a multi-million dollar money media company that has amassed over 7M podcast downloads and has become the world’s #1 investing podcast for women.

All views expressed in this article are the author’s own.

As told to Carine Harb.

Do you have a unique experience or personal story to share? Email the My Turn team at myturn@newsweek.com